Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Leases (2019 - 2025)

Regenxbio (RGNX) has 7 years of Current Leases data on record, last reported at $8.3 million in Q4 2025.

  • For Q4 2025, Current Leases rose 4.86% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $8.3 million, up 4.86%, while the annual FY2025 figure was $8.3 million, 4.86% up from the prior year.
  • Current Leases reached $8.3 million in Q4 2025 per RGNX's latest filing, down from $9.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $9.1 million in Q3 2025 and bottomed at $1.3 million in Q3 2021.
  • Average Current Leases over 5 years is $5.5 million, with a median of $6.5 million recorded in 2023.
  • Peak YoY movement for Current Leases: crashed 62.71% in 2021, then surged 242.29% in 2022.
  • A 5-year view of Current Leases shows it stood at $1.8 million in 2021, then soared by 242.29% to $6.0 million in 2022, then rose by 17.86% to $7.1 million in 2023, then increased by 11.8% to $7.9 million in 2024, then grew by 4.86% to $8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $8.3 million in Q4 2025, $9.1 million in Q3 2025, and $8.0 million in Q2 2025.